Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 4;30(7):oyaf145.
doi: 10.1093/oncolo/oyaf145.

Moving the needle on immune checkpoint inhibitors with novel targets: are we being TIMid or LAGging behind?

Changsu Lawrence Park  1 , Philippe L Bedard  1
Affiliations

Moving the needle on immune checkpoint inhibitors with novel targets: are we being TIMid or LAGging behind?

Changsu Lawrence Park et al. Oncologist. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

PLB: Consultant/Advisory role for: Zymeworks, Lilly, Seattle Genetics, Merck, Amgen, Gilead, Jannsen, Repare, Daiichi Sankyo. Grant/Research support from (Clinical Trials): Amgen, Astra Zeneca, Bayer, Bicara, Boehringer Ingelheim, BristolMyersSquibb, Daiichi Sankyo, Genentech/Roche, Gilead, GlaxoSmithKline, Lilly/Loxo, Medicenna, Merck, Nektar, Novartis, PTC Therapeutics, Sanofi, SeaGen, Servier, SignalChem Life Sciences, Takeda, Zymeworks

Figures

Figure 1:
Figure 1:
Overview of select immune checkpoint receptors and ligands.. Illustrative overview of the immune checkpoint receptors and ligands that were discussed in this editorial. Stimulatory (green dot) and inhibitory (red dot) interactions are depicted. A non-exhaustive list of ICIs in development are listed, with a focus on drugs in phase 3 clinical trials.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. He X, Xu C.. Immune checkpoint signaling and cancer immunotherapy. Cell Res. 2020;30:660-669. https://doi.org/ 10.1038/s41422-020-0343-4 - DOI - PMC - PubMed
    1. Weber JS, D'Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16:375-384. https://doi.org/ 10.1016/S1470-2045(15)70076-8 - DOI - PubMed
    1. Walsh RJ, Sundar R, Lim JSJ.. Immune checkpoint inhibitor combinations-current and emerging strategies. Br J Cancer. 2023;128:1415-1417. https://doi.org/ 10.1038/s41416-023-02181-6 - DOI - PMC - PubMed
    1. Maruhashi T, Sugiura D, Okazaki I-mi, Okazaki T.. LAG-3: from molecular functions to clinical applications. J ImmunoTher Cancer. 2020;8:e001014. https://doi.org/ 10.1136/jitc-2020-001014 - DOI - PMC - PubMed
    1. Long L, Zhang X, Chen F, et al. The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy. Genes Cancer. 2018;9:176-189. https://doi.org/ 10.18632/genesandcancer.180 - DOI - PMC - PubMed

LinkOut - more resources